CMT Breakthrough: FDA Grants Orphan Drug Status to NMD670

by | Jan 7, 2025 | 0 comments

We’re thrilled to share a major breakthrough for the Charcot-Marie-Tooth (CMT) community! NMD Pharma’s investigational drug, NMD670, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). This designation is awarded to therapies with the potential to address rare diseases, like CMT, and comes with benefits that can help accelerate its development.

Why This Matters:

Currently, there are no approved treatments for CMT, but NMD670 is a groundbreaking small molecule designed to improve muscle function by targeting the ClC-1 chloride ion channel in skeletal muscles. For those living with CMT, this could mean better mobility, reduced fatigue, and an enhanced quality of life.

The drug is already in a Phase II clinical trial (SYNAPSE-CMT) to evaluate its safety and effectiveness for CMT types 1 and 2. The FDA’s recognition of NMD670 underscores its potential to meet critical unmet needs in our community, giving us hope for a brighter future.

This exciting progress shows that advancements in CMT research are happening, bringing us closer to treatments that could transform lives.

Interested in Joining the Clinical Trial?

By joining the study, you’ll play a critical role in determining whether this therapy could help others with CMT in the future.

NMD Pharma is currently recruiting eligible patients for the following sites:

NextGen Precision Health, Missouri

Principal Investigator: W. David Arnold, MD

Contact: Neetha Gali | Email: [email protected] | Phone: (573) 882-3065

National Neuromuscular Research Institute, Texas

Principal Investigator: Yessar Hussain, MD

Contact: Stephanie Gonsoulin, RN, BSN | Email: [email protected] | Phone: (512) 920-0140 x210

OSU Department of Neurology Division of Neuromuscular Diseases, Ohio

Principal Investigator: Bakri Elsheikh, MD

Contact: Lischele Watkins, MACPR  | Email: [email protected]

Other locations, including those in New York, Boston, Kansas, Ohio, and Washington will be opening soon.

If you’re living with Charcot-Marie-Tooth (CMT) disease, specifically CMT1 or CMT2 subtypes, you may be eligible to participate in an exciting new clinical trial.

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news